Votrient 200mg

The Votrient 200mg is an inhibitor of tyrosine kinase. The remedy inhibits the process of angiogenesis – the growth of blood vessels, – causing tumor progression. Votrient 200mg is used in the treatment of soft tissue cancer, which can include locally advanced, metastatic renal cell carcinoma (RCC). The efficacy of the remedy was proven in the course of studies, of which 369 people participated, having the abovementioned disease. Respondents who received Votrient 200mg had no progression of the disease for 4.6 months, compared with a placebo group, where the indicator was only about one and a half months.
The drug is taken orally. Do not crush or chew the tablet. The recommended dose is 800 mg / day at one time.

You cannot reduce the intervals between doses. In case of missing the next reception, it is necessary to wait for the next one, without trying to make up the missed one.
Patients who have a creatinine clearance of at least 30 ml / min do not need to adjust the dose. The using of Votrient 200 in persons with severe renal failure, as well as those who are on peritoneal dialysis is prohibited.
In patients with mild violations of liver function, dose adjustment is not performed. The need to reduce the dose to 200 mg / day may occur in patients with moderate hepatic impairment. The using of Votrient 200 in persons with severe hepatic insufficiency is prohibited.
Since taking Votrient 200 can lead to violations in the work of certain organs, during therapy it is necessary to carefully monitor the patient’s condition.
Votrient affects the function of the liver, so its reception can lead to the development of hepatic insufficiency (with a lethal outcome, including). To prevent this undesirable effect before the appointment of the remedy, and further every 4 weeks during therapy and for 4 months after its end, it is necessary to monitor the following indicators: bilirubin level (it should be ≤ 1.5 × CAH) and ALT and ACT activity (it should be ≤ 2 × CAH).

Simultaneous administration of Pazopanib and Simvastatin promotes increased ALT activity. In this case, you need to take extra care and carefully monitor the patient’s condition.
Votrient often causes an increase in blood pressure, so in the treatment process, you need to monitor this indicator and, if necessary, conduct antihypertensive therapy.
During the study, several cases of cardiac dysfunction were recorded with Votrient 200, such as chronic heart failure, and a reduction in the left ventricular ejection fraction. During the treatment it is necessary to regularly measure LVEF. Patients suffering from heart rhythm disturbances during the treatment with Votrient 200 should periodically do ECG. It is necessary to monitor the concentration of electrolytes (calcium, magnesium, potassium).
With caution, Pazopanib is prescribed to people who have a high risk of arterial thrombosis, or who are suffering from this disease.
Since VEGFR inhibitors worsen the wound healing process, the Votrient 200 should be stopped a week before the operation.
In view of the fact that Pazopanib can lead to the development of growth disorders and organ ripening, this remedy is not indicated for use to children under 2 years old.
Pazopanib is not used in combination with other remedies that have an antitumor effect (Pemetrexed, Lapatinib).
To prevent the development of hypothyroidism, it is necessary to monitor the functioning of the thyroid gland.
Votrient 200 should be used with caution:
– if patients have had cases of hemoptysis, various types of internal bleeding;
– if there is a high risk of perforation of the gastrointestinal tract or fistula formation.